Emerging therapeutic targets in asthma: The rationale for mast cell tryptase inhibition

Expert Opinion on Therapeutic Targets

Volumn 3, Issue 2, 1999, Pages 203-212

  Elrod, Kyle C ^a   Numerof, Robert P ^a  

^a Axys Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001064045     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.3.2.203     Document Type: Review

References (82)

1. NATIONAL ASTHMA EDUCATION AND PREVENTION PROGRAM: Highlights of the expert panel 2: guidelines for the diagnosis and management of asthma. National Institutes of Health, Bethesda, MD, USA (1997). NIH Publication No. 97-4051A.
2. NATIONAL CENTER FOR HEALTH STATISTICS: Vital statistics of the United States, 1989, volume ii mortality parts a and b. Public Health Service, Washington, DC, USA (1992).
3. ADAMS P, MARANO M: Current Estimates from the National Health Interview Survey, 1994: National Center for Health Statistics. Vital Health Stat. (1995) 10(193):81-92.
4. SMITH DH, MALONE DC, LAWSON KA et al.: A national estimate of the economic costs of asthma. Am. J. Respir. Crit. Care Med. (1997) 156(3 Pt 1):787-793. (Pubitemid 27396416)
5. GERGEN PJ, WEISS KB: Epidemiology of Asthma. In: Asthma and Rhinitis. Busse WW, Holgate ST (Eds.), Blackwell Scientific Publications, Boston, USA (1995) 16.
6. TAYLOR R, COMINO E, BAUMAN A: Asthma mortality in Australia 1920-94: age, period, and cohort effects. J. Epidemiol. Commun. Health (1997) 51(4):408-411. (Pubitemid 27399530)
7. WOOLCOCK AJ, PEAT JK: Evidence for the increase in asthma worldwide. Ciba. Found. Symp. (1997) 206:122-134.
8. ABERG N, HESSELMAR B, ABERG B, ERIKSSON B: Increase of asthma, allergic rhinitis and eczema in Swedish schoolchildren between 1979 and 1991. Clin. Exp. Allergy (1995) 25(9):815-819.
9. GOREN AI, HELLMANN S: Changing prevalence of asthma among schoolchildren in Israel. Eur. Respir. J. (1997) 10(10):2279-2284. (Pubitemid 27479550)
10. SUISSA S, ERNST P, BOIVIN JF et al.: A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am. J. Respir. Crit. Care Med. (1994) 149(3 Pt 1):604-610.
11. CARTER PM, HEINLY TL, YATES SW, LIEBERMAN PL: Asthma: the irreversible airways disease. J. Investig. Allergol. Clin. Immunol. (1997) 7(6):566-571. (Pubitemid 28045193)
12. EVANS P, O'CONNOR B, FULLER R, BARNES P, CHUNG K: Effect of inhaled corticosteroids on peripheral eosinophil counts and density profiles in asthma. J. Allergy Clin. Immunol. (1993) 91:643-650. (Pubitemid 23062935)
13. DJUKANOVIC R, WILSON JW, BRITTEN KM et al.: Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am. Rev. Respir. Dis. (1992) 145(3):669-674.
14. WANG JH, DEVALIA JL, SAPSFORD RJ, DAVIES RJ: Effect of corticosteroids on release of RANTES and sICAM-1 from cultured human bronchial epithelial cells, induced by TNF-alpha. Eur. Respir. J. (1997) 10(4):834-840. (Pubitemid 27180195)
15. CALHOUN W, SEDGWICK J, BUSSE W: The role of eosinophils in the pathophysiologoy of asthma. Ann. NY Acad. Sci. (1991) 629:62-72.
16. HOLGATE S, ROCHE W, CHURCH M: The role of the eosinophil in asthma. Am. Rev. Respir. Dis. (1991) 143:566-570.
17. SIMON MR, HOUSER WL, SMITH KA, LONG PM: Esophageal candidiasis as a complication of inhaled corticosteroids. Ann. Allergy Asthma Immunol. (1997) 79(4):333-338. (Pubitemid 27463192)
18. WILLIAMSON IJ, MATUSIEWICZ SP, BROWN PH, GREENING AP, CROMPTON GK: Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur. Respir. J. (1995) 8(4):590-592.
19. ERICKSON SR, HORTON A, KIRKING DM: Assessing metered-dose inhaler technique: comparison of observation vs. patient self-report. J. Asthma (1998) 35(7):575-583. (Pubitemid 28566877)
20. SORKNESS CA: The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma. Pharmacotherapy (1997) 17(1 Pt 2):50S-54S. (Pubitemid 27057113)
21. CHURCH M, LOWMAN M, REES P, BENYON R: Penary Lecture: mast cells, neuropeptides and inflammation. Agents Actions (1989) 27:8-16. (Pubitemid 19108484)
22. POLLART SM, CHAPMAN MD, FIOCCO GP, ROSE G, PLATTS-MILLS TA: Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits. J. Allergy Clin. Immunol. (1989) 83(5):875-882. (Pubitemid 19147178)
23. WILLS-KARP M, LUYIMBAZI J, XU X et al.: Interleukin-13: central mediator of allergic asthma. Science (1998) 282:2258-2261. (Pubitemid 29004074)
24. EMSON CL, BELL SE, JONES A, WISDEN W, MCKENZIE AN: Interleukin (IL)-4-independent induction of immunoglobulin (Ig)E, and perturbation of T cell development in transgenic mice expressing IL-13. J. Exp. Med. (1998) 188(2):399-404. (Pubitemid 28357768)
25. SCHWARTZ LB, LEWIS RA, AUSTEN KF: Tryptase from human pulmonary mast cells. Purification and characterization. J. Biol. Chem. (1981) 256(22):11939-11943.
26. CRAIG SS, SCHWARTZ LB: Tryptase and chymase, markers of distinct types of human mast cells. Immunol. Res. (1989) 8(2):130-148. (Pubitemid 19135916)
27. IRANI AA, SCHECHTER NM, CRAIG SS, DE BLOIS G, SCHWARTZ LB: Two types of human mast cells that have distinct neutral protease compositions. Proc. Natl. Acad. Sci. USA (1986) 83(12):4464-4468. (Pubitemid 16057069)
28. SCHWARTZ LB, IRANI AM, ROLLER K, CASTELLS MC, SCHECHTER NM: Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J. Immunol. (1987) 138(8):2611-2615. (Pubitemid 17051840)
29. MILLER JS, WESTIN EH, SCHWARTZ LB: Cloning and characterization of complementary DNA for human tryptase. J. Clin. Invest. (1989) 84(4):1188-1195. (Pubitemid 19247590)
30. VANDERSLICE P, BALLINGER SM, TAM EK et al.: Human mast cell tryptase: multiple cDNAs and genes reveal a multigene serine protease family. Proc. Natl. Acad. Sci. USA (1990) 87(10):3811-3815.
31. XIA HZ, KEPLEY CL, SAKAI K et al.: Quantitation of tryptase, chymase, Fc epsilon RI alpha, and Fc epsilon RI gamma mRNAs in human mast cells and basophils by competitive reverse transcription-polymerase chain reaction. J. Immunol. (1995) 154(10):5472-5480.
32. SCHWARTZ LB, SAKAI K, BRADFORD TR et al.: The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J. Clin. Invest. (1995) 96(6):2702-2710.
33. WENZEL S, IRANI AM, SANDERS JM, BRADFORD TR, SCHWARTZ LB: Immunoassay of tryptase from human mast cells. J. Immunol. Methods (1986) 86(1):139-142. (Pubitemid 16187300)
34. ENANDER I, MATSSON P, NYSTRAND J et al.: A new radioimmunoassay for human mast cell tryptase using monoclonal antibodies. J. Immunol. Methods (1991) 138(1):39-46.
35. SCHWARTZ LB, METCALFE DD, MILLER JS, EARL H, SULLIVAN T: Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. New Engl. J. Med. (1987) 316(26):1622-1626. (Pubitemid 17082588)
36. WENZEL SE, FOWLER AAD, SCHWARTZ LB: Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma. Am. Rev. Respir. Dis. (1988) 137(5):1002-1008.
37. SCHWARTZ LB, BRADFORD TR, LITTMAN BH, WINTROUB BU: The fibrinogenolytic activity of purified tryptase from human lung mast cells. J. Immunol. (1985) 135(4):2762-2767. (Pubitemid 16217148)
38. THOMAS VA, WHEELESS CJ, STACK MS, JOHNSON DA: Human mast cell tryptase fibrinogenolysis: kinetics, anticoagulation mechanism, and cell adhesion disruption. Biochemistry (1998) 37(8):2291-2298. (Pubitemid 28119302)
39. GRUBER BL, MARCHESE MJ, SUZUKI K et al.: Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J. Clin. Invest. (1989) 84(5):1657-1662. (Pubitemid 19272256)
40. GRUBER BL, SCHWARTZ LB, RAMAMURTHY NS, IRANI AM, MARCHESE MJ: Activation of latent rheumatoid synovial collagenase by human mast cell tryptase. J. Immunol. (1988) 140(11):3936-3942.
41. LOHI J, HARVIMA I, KESKI-OJA J: Pericellular substrates of human mast cell tryptase: 72,000 Dalton gelatinase and fibronectin. J. Cell. Biochem. (1992) 50(4):337-349. (Pubitemid 23005800)
42. KIELTY CM, LEES M, SHUTTLEWORTH CA, WOOLLEY D: Catabolism of intact Type VI collagen microfibrils: susceptibility to degradation by serine proteinases. Biochem. Biophys. Res. Commun. (1993) 191(3):1230-1236. (Pubitemid 23231622)
43. STACK MS, JOHNSON DA: Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J. Biol. Chem. (1994) 269(13):9416-9419. (Pubitemid 24196529)
44. TAM EK, CAUGHEY GH: Degradation of airway neuropeptides by human lung tryptase. Am. J. Respir. Cell. Mol. Biol. (1990) 3(1):27-32.
45. FRANCONI GM, GRAF PD, LAZARUS SC, NADEL JA, CAUGHEY GH: Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret. J. Pharmacol. Exp. Ther. (1989) 248(3):947-951. (Pubitemid 19100739)
46. CARDELL LO, UDDMAN R, EDVINSSON L: Low plasma concentrations of VIP and elevated levels of other neuropeptides during exacerbations of asthma. Eur. Respir. J. (1994) 7(12):2169-2173.
47. PALMER JB, CUSS FM, BARNES PJ: VIP and PHM and their role in non-adrenergic inhibitory responses in isolated human airways. J. Appl. Physiol. (1986) 61(4):1322-1328. (Pubitemid 17179315)
48. JOHNSON D, KRENGER W: Interactions of mast cells with the nervous system-recent advances. Neurochem. Res. (1992) 17(9):939-951.
49. MAIER M, SPRAGG J, SCHWARTZ LB: Inactivation of human high molecular weight kininogen by human mast cell tryptase. J. Immunol. (1983) 130(5):2352-2356. (Pubitemid 13086785)
50. PROUD D, SIEKIERSKI ES, BAILEY GS: Identification of human lung mast cell kininogenase as tryptase and relevance of tryptase kininogenase activity. Biochem. Pharmacol. (1988) 37(8):1473-1480. (Pubitemid 18093340)
51. WALLS AF, BENNETT AR, SUEIRAS-DIAZ J, OLSSON H: The kininogenase activity of human mast cell tryptase. Biochem. Soc. Trans. (1992) 20(3):260S.
52. IMAMURA T, DUBIN A, MOORE W, TANAKA R, TRAVIS J: Induction of vascular permeability enhancement by human tryptase: dependence on activation of prekallikrein and direct release of bradykinin from kininogens. Lab. Invest. (1996) 74(5):861-870. (Pubitemid 26152656)
53. FULLER RW, DIXON CM, CUSS FM, BARNES PJ: Bradykinin-induced bronchoconstriction in humans. Mode of action. Am. Rev. Respir. Dis. (1987) 135(1):176-180.
54. BARNES PJ: Effect of bradykinin on airway function. Agents Actions Suppl. (1992) 38(Pt 3):432-438.
55. SEKIZAWA K, CAUGHEY GH, LAZARUS SC, GOLD WM, NADEL JA: Mast cell tryptase causes airway smooth muscle hyper-responsiveness in dogs. J. Clin. Invest. (1989) 83(1):175-179. (Pubitemid 19048420)
56. RUOSS SJ, HARTMANN T, CAUGHEY GH: Mast cell tryptase is a mitogen for cultured fibroblasts. J. Clin. Invest. (1991) 88(2):493-499.
57. HARTMANN T, RUOSS SJ, RAYMOND WW, SEUWEN K, CAUGHEY GH: Human tryptase as a potent, cell-specific mitogen: role of signaling pathways in synergistic responses. Am. J. Physiol. (1992) 262(5 Pt 1):L528-534.
58. CAIRNS JA, WALLS AF: Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J. Immunol. (1996) 156(1):275-283. (Pubitemid 26006973)
59. BROWN JK, TYLER CL, JONES CA et al.: Tryptase, the dominant secretory granular protein in human mast cells, is a potent mitogen for cultured dog tracheal smooth muscle cells. Am. J. Respir. Cell. Mol. Biol. (1995) 13(2):227-236.
60. HARTMANN T, RUOSS SJ, CAUGHEY GH: Modulation of thrombin and thrombin receptor peptide mitogenicity by human lung mast cell tryptase. Am. J. Physiol. (1994) 267(2 Pt 1):L113-119.
61. NUMEROF R, MOORE W, TANAKA R: Activation of human eosinophils, but not neutrophils, in response to mast cell tryptase. Am. J. Resp. Crit. Care (1996) 153:A202.
62. ERGER RA, CASALE TB: Interleukin-8 is a potent mediator of eosinophil chemotaxis through endothelium and epithelium. Am. J. Physiol. (1995) 268(1 Pt 1):L117-122.
63. HE S, GACA MD, WALLS AF: A role for tryptase in the activation of human mast cells: modulation of histamine release by tryptase and inhibitors of tryptase. J. Pharmacol. Exp. Ther. (1998) 286(1):289-297. (Pubitemid 28318002)
64. NYSTEDT S, EMILSSON K, WAHLESTEDT C, SUNDELIN J: Molecular cloning of a potential proteinase activated receptor. Proc. Natl. Acad. Sci. USA (1994) 91:9208-9212. (Pubitemid 24297883)
65. MOLINO M, BARNATHAN ES, NUMEROF R et al.: Interactions of mast cell tryptase with thrombin receptors and PAR-2. J. Biol. Chem. (1997) 272(7):4043-4049. (Pubitemid 27078466)
66. MOLINARI JF, SCURI M, MOORE WR et al.: Inhaled tryptase causes bronchoconstriction in sheep via histamine release. Am. J. Respir. Crit. Care Med. (1996) 154(3 Pt 1):649-653. (Pubitemid 26327286)
67. MOLINARI JF, MOORE WR, CLARK J et al.: Role of tryptase in immediate cutaneous responses in allergic sheep. J. Appl. Physiol. (1995) 79(6):1966-1970. (Pubitemid 26013147)
68. HE S, PENG Q, WALLS AF: Potent induction of a neutrophil and eosinophil-rich infiltrate in vivo by human mast cell tryptase: selective enhancement of eosinophil recruitment by histamine. J. Immunol. (1997) 159(12):6216-6225. (Pubitemid 127471563)
69. HE S, WALLS AF: Human mast cell tryptase: a stimulus of microvascular leakage and mast cell activation. Eur. J. Pharmacol. (1997) 328(1):89-97. (Pubitemid 27241401)
70. TRAVIS J, SALVENSEN GS: Human plasma proteinase inhibitors. Ann. Rev. Biochem. (1983) 52:655-709. (Pubitemid 13030691)
71. TRAVIS J: Target enzymes for plasma proteinase inhibitors. Folia Histochemica Et Cytobiologica (1986) 24(2):117-124. (Pubitemid 17205726)
72. LILJA H: Regulation of the enzymatic activity of prostate-specific antigen and its reactions with extracellular protease inhibitors in prostate cancer. Scand. J. Clin. Invest. (1995) 55(Suppl. 220):47-56.
73. SCHECHTER NM, ENG GY, SELWOOD T, MCCASLIN DR: Structural changes associated with the spontaneous inactivation of the serine proteinase human tryptase. Biochemistry (1995) 34(33):10628-10638.
74. SELWOOD T, MCCASLIN DR, SCHECHTER NM: Spontaneous inactivation of human tryptase involves conformational changes consistent with conversion of the active site to a zymogen-like structure. Biochemistry (1998) 37(38):13174-13183. (Pubitemid 28449561)
75. SCHWARTZ LB, BRADFORD TR, LEE DC, CHLEBOWSKI JF: Immunologic and physicochemical evidence for conformational changes occurring on conversion of human mast cell tryptase from active tetramer to inactive monomer. Production of monoclonal antibodies recognizing active tryptase. J. Immunol. (1990) 144(6):2304-2311.
76. KOZIK A, POTEMPA J, TRAVIS J: Spontaneous inactivation of human lung tryptase as probed by size-exclusion chromatography and chemical crosslinking: dissociation of active tetrameric enzyme into inactive monomers is the primary event of the entire process. Biochim. Biophys. Acta (1998) 1385(1):139-148. (Pubitemid 28277052)
77. ALTER SC, KRAMPS JA, JANOFF A, SCHWARTZ LB: Interactions of human mast cell tryptase with biological protease inhibitors. Arch. Biochem. Biophys. (1990) 276(1):26-31. (Pubitemid 20041812)
78. ELROD KC, MOORE WR, ABRAHAM WM, TANAKA RD: Lactoferrin, a potent tryptase inhibitor, abolishes late-phase airway responses in allergic sheep. Am. J. Respir. Crit. Care Med. (1997) 156(2 Pt 1):375-381. (Pubitemid 27351967)
79. RICE K, TANAKA R, KATZ B, NUMEROF R, MOORE W: Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr. Pharm. Design (1998) 4:393-408.
80. CLARK JM, ABRAHAM WM, FISHMAN CE et al.: Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep. Am. J. Respir. Crit. Care Med. (1995) 152(6 Pt 1):2076-2083.
81. ABRAHAM WM, LANES S, STEVENSON JS, YERGER LD: Effect of an inhaled glucocorticosteroid (budesonide) on post-antigen induced increases in airway responsiveness. Bull. Eur. Physiopathol. Respir. (1986) 22:387-392. (Pubitemid 16001214)
82. KRISHNA M, CHAUHAN A, LITTLE L et al.: Effect of inhaled APC-366 on allergen-induced bronchoconstriction and airway hyper-responsiveness to histamine in atopic asthmatics. Am. J. Respir. Crit. Care Med. (1998) 157:A456.